There have been remarkable results of anti-PD1 causing remissions in heavily pretreated Hodgkin's Lymphoma patients.
Here we examine why this cancer immunotherapy can change the way Hodgkin's Lymphoma patients are treated in the future.
Hodgkin's Lymphoma is a good target for anti-PD1.
